MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 301–400 of 1,006
Villar, A. V., García, R., Merino, D., Llano, M., Cobo, M., Montalvo, C., Martín-Durán, R., Hurlé, M. A., & Nistal, J. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.07.021 · Cited by 150
“Degenerative aortic stenosis (AS) has become themost frequent type of valvular disease in industrialized countries (2–7% of the population older than 65 years) and its incidence is rising in parallel to the c stenosis; Col, collagen; ECM, e; miRNA, microRNA; PDCD4, nd tensin homolog; RECK, tifs; SPRY1, sprouty homolog…”
BackgroundResultInfluentialmiR-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy
Wang, K., Long, B., Zhou, J., & Li, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.098004 · Cited by 162
MicroRNAs in control of cardiac hypertrophy
Martins, P. A. D. C., & Windt, L. J. D. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs013 · Cited by 165
MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis
Kadera, B. E., Li, L., Toste, P. A., Wu, N., Adams, C., Dawson, D. W., & Donahue, T. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071978 · Cited by 147
“In the heart, miR-21 expression increases in cardiac fibroblasts of the failing heart [33].”
BackgroundmicroRNA in the development of diabetic complications
McClelland, A., & Kantharidis, P. (2013) · Clinical Science · doi:10.1042/cs20130079 · Cited by 159
Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis
Wang, J., Liew, O. W., Richards, M., & Chen, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050749 · Cited by 160
Zhang, P., Su, J., & Mende, U. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01167.2011 · Cited by 154
Polyakova, V. O., Loeffler, I., Hein, S., Miyagawa, S., Piotrowska, I., Dammer, S., Risteli, J., Schaper, J., & Sawa Kostin, D. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.053 · Cited by 165
Meloni, M., Marchetti, M., Garner, K., Littlejohns, B., Sala-Newby, G., Xenophontos, N., Floris, I., Suleiman, M.-S., Madeddu, P., Caporali, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.89 · Cited by 145
Reciprocal Repression Between MicroRNA-133 and Calcineurin Regulates Cardiac Hypertrophy
Dong, D., Chen, C., Huo, R., Wang, N., Li, Z., Tu, Y.-J., Hu, J., Chu, X., Huang, W., & Yang, B. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.139519 · Cited by 145
Koh, W., Sheng, C. T., Tan, B., Lee, Q. Y., Kuznetsov, V., Kiang, L. S., & Tanavde, V. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-s1-s6 · Cited by 141
“miRNAs like miR 21 [ 20 ], miR 133 and miR 30 [21] have been shown to play a role in cardiac remodelling in infracted hearts.”
BackgroundTherapeutic Targets in Heart Failure
Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J., & Gheorghiade, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.068 · Cited by 145
“Newer agents (Table 2) such as potent and selective nonsteroidal mineralocorticoid antagonists (114), serelaxin (32,115), and microribonucleic acids (miRs) (48,116) offer novel ways to treat ECM expansion caused by myocardial fibrosis.”
BackgroundEffect of miR-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in kk-ay Diabetic Nephropathy Mice
Wang, J., Gao, Y., Ma, M.-F., Li, M., Zou, D., Yang, J., Zhu, Z., & Zhao, X. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9539-2 · Cited by 147
Molecular basis of organ fibrosis: Potential therapeutic approaches
Ghosh, A. K., Quaggin, S. E., & Vaughan, D. E. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213489441 · Cited by 155
“Thum et al.(205) demonstrate that the level of miR-21 is significantly elevated in failing hearts and in a pressure overload-induced animal model of cardiac fibrosis.”
BackgroundMicroRNAs and atrial fibrillation: mechanisms and translational potential
Luo, X., Yang, B., & Nattel, S. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.178 · Cited by 151
Crucial Role of miR-433 in Regulating Cardiac Fibrosis
Tao, L., Bei, Y., Chen, P., Lei, Z., Fu, S., Zhang, H., Xu, J., Che, L., Chen, X., Sluijter, J. P., et al. (2016) · Theranostics · doi:10.7150/thno.15007 · Cited by 143
“It has been suggested that dysregulated miRNAs such as miR-21 and miR-29b, contribute to cardiac fibrosis [16, 18].”
Circulating blood cells and extracellular vesicles in acute cardioprotection
Davidson, S. M., Andreadou, I., Barile, L., Birnbaum, Y., Cabrera-Fuentes, H. A., Cohen, M. V., Downey, J. M., Girao, H., Pagliaro, P., Penna, C., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvy314 · Cited by 137
“However, miR-21 also appears to contribute to remodelling and fibrosis in the failing heart.(84)”
BackgroundmiR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts
Kashiyama, K., Mitsutake, N., Matsuse, M., Ogi, T., Saenko, V. A., Ujifuku, K., Utani, A., Hirano, A., & Yamashita, S. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.22 · Cited by 139
“miR-21 expression is increased selectively in fibroblasts in failing heart and controls interstitial fibrosis and cardiac hypertrophy (Thum et al., 2008).”
BackgroundMicroRNA-21 in Glomerular Injury
Lai, J. Y., Luo, J., O'Connor, C. L., Jing, X., Nair, V., Ju, W., Randolph, A. E., Ben‐Dov, I. Z., Matar-Ujvary, R., Briskin, D., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121274 · Cited by 148
Self-citationHypertrophic cardiomyopathy: genetics and clinical perspectives
Wolf, C. M. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.02.01 · Cited by 156
“RNA based therapies in HCM have so far been shown to be efficient in mouse models (226) and in several in vivo studies (227), but no”
BackgroundAlibhai, F. J., Lim, F., Yeganeh, A., DiStefano, P. V., Binesh‐Marvasti, T., Belfiore, A., Wlodarek, L., Gustafson, D., Millar, S., Li, S., et al. (2020) · Aging Cell · doi:10.1111/acel.13103 · Cited by 140
“Consistent with this notion, antagomiRs targeting miR-146a (Jiang et al., 2012) or miR-21 (Thum et al., 2008) can improve age-associated phenotypes.”
BackgroundMicroRNAs in skin and wound healing
Banerjee, J., Chan, Y. C., & Sen, C. K. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00157.2010 · Cited by 134
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Greene, S. J., Gheorghiade, M., Borlaug, B. A., Pieske, B. M., Vaduganathan, M., Burnett, J. C. J., Roessig, L., Stasch, J., Solomon, S. D., Paulus, W. J., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000536 · Cited by 150
MicroRNA-494 Reduces ATF3 Expression and Promotes AKI
Lan, Y., Chen, H.-H., Lai, P., Cheng, C., Huang, Y.-T., Lee, Y., Chen, T., & Lin, H. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050438 · Cited by 148
AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury
Hinkel, R., Ramanujam, D., Kaczmarek, V., Howe, A., Klett, K., Beck, C., Dueck, A., Thum, T., Laugwitz, K.-L., Maegdefessel, L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.041 · Cited by 139
“Its inhibition in murine disease models was found to prevent the development of pressure overload–induced myocardial fibrosis and dysfunction but was also effective when given in established disease (8).”
BackgroundResultSelf-citationDifferential Expression of Matrix Metalloproteases in Human Fibroblasts with Different Origins
Lindner, D., Zietsch, C., Becher, P. M., Schulze, K., Schultheiss, H., Tschöpe, C., & Westermann, D. (2012) · Biochemistry Research International · doi:10.1155/2012/875742 · Cited by 153
“To exclude contaminations with other cells than the expected fibroblasts, for instance, endothelial cells or muscle cells such as cardiomyocytes from the heart [18], we stained the cultured cells further with the muscle marker desmin and the endothelial marker CD31.”
BackgroundLing, M., Li, Y., Xu, Y., Pang, Y., Shen, L., Jiang, R., Zhao, Y., Yang, X., Zhang, J., Zhou, J., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.020 · Cited by 142
Atrial fibrillation and microRNAs
Santulli, G., Iaccarino, G., LUCA, N. D., Trimarco, B., & Condorelli, G. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00015 · Cited by 144
“…its downstream target Sprouty (Spry1), a master regulator of fibroblast survival and growth factor secretion, controlling the extent of interstitial fibrosis (Thum et al., 2008), has been demonstrated both in AF patients, in which atria miR-21 is increased, and murine models (Adam et al., 2012).”
BackgroundLorenzen, J. M., Schauerte, C., Hübner, A., Kölling, M., Martino, F., Scherf, K., Bátkai, S., Zimmer, K., Foinquinos, A., Kaucsár, T., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv109 · Cited by 137
“MiR-21 has previously been shown to serve as master regulatorof fibrosis development.(1,10) The resultsof the global”
BackgroundMethodSelf-citationMicroRNAs in Hypertension: Mechanisms and Therapeutic Targets
Bátkai, S., & Thum, T. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0235-6 · Cited by 145
“MicroRNA-21, implicated in cardiac remodeling [58], has been found to be a critical regulator of VSMC proliferation and an inhibitor of apoptosis by targeting phosphate and tensin homolog (PTEN) and Bcl-2 expression [59].”
Self-citationZhao, B., Chen, S., Liu, J., Yuan, Z., Qi, X., Qin, J., Zheng, X. M., Shen, X., Yu, Y., Qnin, T. J., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01655.x · Cited by 136
Role of MicroRNAs in Cardiac Remodeling and Heart Failure
Topkara, V. K., & Mann, D. L. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6289-5 · Cited by 145
“expressed in cardiac fibroblast compartment [29].”
BackgroundSong, X., Li, Q., Lin, L., Wang, X., Li, D., Wang, G., Ren, A., Wang, Y., Qin, Y., Yuan, W., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22217 · Cited by 142
“…aberrantly regulated miRNAs, miR-1, miR-133 JOURNAL OF CELLULAR PHYSIOLOGY and miR-21 had been reported to play an important role in heart diseases (Care et al., 2007; Sayed et al., 2007; Thum et al., 2008), while the function of miR-199a in cardiac hypertrophy or heart failure remains unclear.”
BackgroundResultTargeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells
Shu, M., Zheng, X., Wu, S., Lu, H., Leng, T., Zhu, W., Zhou, Y., Ou, Y., Lin, X., Lin, Y., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-59 · Cited by 152
“This “miRNA targeting therapy” has been given more and more attention and successfully demonstrated in several human diseases [47-50], indicating a potential application of this approach in clinical settings.”
BackgroundHeart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology
Gevaert, A. B., Boen, J. R. A., Segers, V. F. M., & Craenenbroeck, E. M. V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00638 · Cited by 154
Ravassa, S., López, B., Treibel, T. A., José, G. S., Losada-Fuentenebro, B., Tapia, L., Bayés‐Genís, A., Díez, J., & González, A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101194 · Cited by 152
“MiR-21 inhibition with antago-mirs prevents the development of cardiac fibrosis after TAC if administered early after surgery and attenuates fibrosis progression if administered 3 weeks after surgery (Thum et al., 2008).”
BackgroundO’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 146
Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure
Dirkx, E., Gladka, M. M., Philippen, L. E., Armand, A., Kinet, V., Leptidis, S., el Azzouzi, H., Salic, K., Bourajjaj, M., da Silva, G. J. J., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2866 · Cited by 141
Self-citationRosell, R., Wei, J., & Tarón, M. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.001 · Cited by 137
Novel therapeutic approaches to post-infarction remodelling
Fraccarollo, D., Galuppo, P., & Bauersachs, J. K. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs109 · Cited by 151
Self-citationNon-Coding RNA-Targeted Therapy: A State-of-the-Art Review
Nappi, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073630 · Cited by 146
“Coronary catheterization, which is now a clinically routinized procedure, has been used to administer microRNA drugs in both small [18] and large animals [15,27,194].”
BackgroundMethodInduction of Specific MicroRNAs Inhibits Cutaneous Wound Healing
Pastar, I., Khan, A. A., Stojadinovic, O., Lebrun, E. A., Medina, M. C., Brem, H., Kirsner, R. S., Jimenez, J. J., Leslie, C., & Tomic-Canic, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382135 · Cited by 132
Searching for New Mechanisms of Myocardial Fibrosis with Diagnostic and/or Therapeutic Potential
Heymans, S. R. B., González, A., Pizard, A., Papageorgiou, A., López‐Andrés, N., Jaisser, F., Thum, T., Zannad, F. M., & Díez, J. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.312 · Cited by 139
Self-citationIdentification of Sensitive Serum microRNA Biomarkers for Radiation Biodosimetry
Jacob, N. K., Cooley, J. V., Yee, T. N., Jacob, J., Alder, H., Wickramasinghe, P., Maclean, K. H., & Chakravarti, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057603 · Cited by 139
“Several evolutionarily conserved and functionally significant miRNAs, such as miRNA-150, miRNA21, miRNA-29a and miRNA-23a, were also detected in serum samples [25,26,27,28,29].”
BackgroundThe Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schäfers, H.-J., Böhm, M., & Laufs, U. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519256 · Cited by 133
“MicroRNA-21 increases fibroblast survival that leads to cardiac fibrosis and dysfunction (36).”
BackgroundBihrer, V., Waidmann, O., Friedrich‐Rust, M., Forestier, N., Süsser, S., Haupenthal, J., Welker, M., Shi, Y., Peveling‐Oberhag, J., Polta, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026971 · Cited by 145
“miR-21 has also been linked to fibrosis in the lung [14], heart [15] and liver [9].”
BackgroundNakata, K., Sugi, Y., Narabayashi, H., Kobayakawa, T., Nakanishi, Y., Tsuda, M., Hosono, A., Kaminogawa, S., Hanazawa, S., & Takahashi, K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788596 · Cited by 130
Liu, Z., Chen, X., Zhang, Z., Zhang, X., Saunders, L. R., Zhou, Y., & Ma, P. X. (2018) · ACS Nano · doi:10.1021/acsnano.7b08976 · Cited by 134
Haghikia, A., Missol‐Kolka, E., Tsikas, D., Venturini, L., Brundiers, S., Castoldi, M., Muckenthaler, M. U., Eder, M., Stapel, B., Thum, T., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq369 · Cited by 140
“In this regard, it has been shown that miRNAs either in CMs or the non-myocyte fraction modulate cardiac pathophysiology.(8,9)”
Self-citationmicroRNA regulation of Wnt signaling pathways in development and disease
Song, J. L., Nigam, P., Tektas, S. S., & Selva, E. M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.03.018 · Cited by 145
Yildirim, S. S., Akman, D., Catalucci, D., & Turan, B. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9672-y · Cited by 136
“[37] on the relation of contribution of miR-21 to myocardial disease by stimulating MAP kinase signaling in mouse fibroblasts seem to be in line with our data of upregulated miR-21 level.”
ResultPolytarchou, C., Iliopoulos, D., Hatziapostolou, M., Kottakis, F., Maroulakou, I., Struhl, K., & Tsichlis, P. N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0365 · Cited by 128
“Oxygen deprivation promotes the induction of miR-21 via an Akt2-dependent process and miR-21 inhibits the expression of the D3 phosphoinositide phosphatase PTEN, the proapoptotic inhibitor of protein translation PDCD4 and the inhibitor of ERK activation Spry1.”
InfluentialmicroRNAs modulate iPS cell generation
Yang, C.-S., Li, Z., & Rana, T. M. (2011) · RNA · doi:10.1261/rna.2664111 · Cited by 129
“2010) and ERK1/2 (Thum et al. 2008) pathways, both of which have been shown to influence reprogramming and the ES cell ground state (Ichida et al.”
BackgroundInfluentialCui, H., He, Y., Chen, S., Zhang, D., Yu, Y., & Fan, C. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.11.006 · Cited by 129
“Several previous reports indicated that the expression of collagens and other ECM components is controlled by miR-21,(36,41,42) which in turn is upregulated by TGF-b1 in several pathological conditions.(34,49) Although TGF-b1 plays an important role in mediating the increased expression of miR-21, there are other yet…”
BackgroundTargeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression
Lin, R., Chen, L., Chen, G., Hu, C., Jiang, S., Sevilla, J., Wan, Y., Sampson, J. H., Zhu, B., & Li, Q.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76561 · Cited by 140
Sprouty proteins: modified modulators, matchmakers or missing links?
Guy, G. R., Jackson, R. A., Yusoff, P., & Chow, S. Y. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0110 · Cited by 129
MicroRNA: A new therapeutic strategy for cardiovascular diseases
Samanta, S., Balasubramanian, S., Rajasingh, S., Patel, U., Dhanasekaran, A., Dawn, B., & Rajasingh, J. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.02.004 · Cited by 135
“Silencing of miRNA-21 with an antagomir results in the reduction of cardiac ERK-MAPK activity, inhibition of interstitial fibrosis, and improvement of cardiac dysfunction [82].”
Zhang, Z., Zha, Y., Hu, W., Huang, Z., Gao, Z., Zang, Y., Chen, J., Dong, L., & Zhang, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517953 · Cited by 128
Lin, Y., Ding, D., Huang, Q., Liu, Q., Lu, H., Lu, Y.-Y., Chi, Y., Sun, X., Ye, G., Zhu, H., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.05.001 · Cited by 135
“induced cardiac hypertrophy and fibrosis in mice [59] but miR-21-deficient mice did not show any cardiac differences compared with WT mice under pressure overload [60].”
BackgroundmiR-21 deficiency inhibits osteoclast function and prevents bone loss in mice
Hu, C.-H., Sui, B.-D., Du, F.-Y., Shuai, Y., Zheng, C.-X., Zhao, P., Yu, X.-R., & Jin, Y. (2017) · Scientific Reports · doi:10.1038/srep43191 · Cited by 127
Epigenetic modifications in cardiovascular disease
Lorenzen, J. M., Martino, F., & Thum, T. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0245-9 · Cited by 141
“An array of studies elucidated a disease-specific role for selected miRNAs (for instance, miR-21 and miR-29 in cardiac fibrosis) [73, 78].”
BackgroundSelf-citationVarga, Z. V., Zvara, Á., Faragó, N., Kocsis, G. F., Pipicz, M., Gáspár, R., Bencsik, P., Görbe, A., Csonka, C., Puskás, L. G., et al. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00812.2013 · Cited by 134
Self-citationPreclinical development of a MicroRNA-based therapy for elderly patients with myocardial infarction
Gupta, S. K., Foinquinos, A., Thum, S., Remke, J., Zimmer, K., Bauters, C., de Groote, P., Boon, R. A., de Windt, L. J., Preissl, S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.739 · Cited by 125
Self-citationKoga, K., Kenessey, Á., Powell, S. R., Sison, C. P., Miller, E. J., & Ojamaa, K. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3163 · Cited by 125
“1A and C, cardiac fibroblasts at the third passage in culture were a relatively homogeneous population of spindle-shaped cells that expressed prolyl-4-hydroxylase (P4HB), a fibroblast protein marker (46), and did not express myocyte-specific a-actinin, as shown for mouse whole-heart homogenate.”
MicroRNA‐101 suppresses liver fibrosis by targeting the TGF β signalling pathway
Tu, X., Zhang, H., Zhang, J., Zhao, S., Zheng, X., Zhang, Z., Zhu, J., Chen, J., Dong, L., Zang, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4373 · Cited by 125
“Inhibition of miR-101 in vivo aggravated hepatic fibrosis Inhibition of miRNAs with modified antisense oligoribonucleotides has been shown to be an efficient and specific approach to silence endogenous miRNAs in multiple tissues [32,33].”
BackgroundMicroRNA Regulation and Cardiac Calcium Signaling: Role in Cardiac Disease and Therapeutic Potential
Harada, M., Luo, X., Murohara, T., Yang, B., Dobrev, D., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.301798 · Cited by 133
“virus, as well as in several animal model studies of cardiovascular diseases.(15,25,31,115,116) One major concern about antimiRs is”
BackgroundBigot, A., Duddy, W. J., Ouandaogo, Z. G., Negroni, E., Mariot, V., Ghimbovschi, S., Harmon, B., Wielgosik, A., Loiseau, C., Devaney, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.067 · Cited by 125
Matricellular Protein CCN5 Reverses Established Cardiac Fibrosis
Jeong, D., Lee, M.-A., Li, Y., Yang, D. K., Kho, C., Oh, J. G., Hong, G., Lee, A., Song, M. H., LaRocca, T. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.030 · Cited by 132
“Although CF has conventionally been regarded as a secondary phenomenon, it has also been suggested to play a primary role in the progression of HF (8).”
BackgroundMicroRNA-133 Modulates the β 1 -Adrenergic Receptor Transduction Cascade
Castaldi, A., Zaglia, T., Mauro, V. D., Carullo, P., Viggiani, G., Borile, G., Stefano, A. B. D., Schiattarella, G. G., Gualazzi, M. G., Elia, L., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303252 · Cited by 125
Liu, S., Liu, C., Lv, X., Cui, B., Yan, J., Li, Y., Li, K., Hua, F., Zhang, X., Yu, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.008 · Cited by 137
miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8
Yan, M., Chen, C., Gong, W., Yin, Z., Zhou, L., Chaugai, S., & Wang, D. W. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu254 · Cited by 131
Kim, C., Hu, B., Jadhav, R. R., Jin, J., Zhang, H., Cavanagh, M., Akondy, R. S., Ahmed, R., Weyand, C. M., & Goronzy, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.074 · Cited by 136
“miR-21 Activates the Mammalian Target of Rapamycin and Extracellular Signal-Regulated Kinase Signaling Pathways by Targeting PTEN and SPRY1 Signaling molecules directly targeted by miR-21 in naive CD4+ T cells include PTEN and SPRY1, as shown by increased protein levels after antagonizing miR-21 (Figure 5A; Meng et al…”
BackgroundmiR-21 in Human Cardiomyopathies
Surina, Fontanella, R. A., Scisciola, L., Marfella, R., Paolisso, G., & Barbieri, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.767064 · Cited by 143
Angiotensin II Regulates microRNA-132/-212 in Hypertensive Rats and Humans
Eskildsen, T. V., Jeppesen, P., Schneider, M., Nossent, A. Y., Sandberg, M. B., Hansen, P., Jensen, C. H., Hansen, M. L., Marcussen, N., Rasmussen, L. M., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611190 · Cited by 124
“miR-21, miR-155 and miR-221/222 have recently been shown to regulate AngII signaling in cardiac fibroblasts [14–16] and in endothelial cells [17], while miR-29 regulates fibrotic pathways [18].”
BackgroundMicroRNAs in Myocardial Infarction
Fiedler, J., & Thum, T. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300137 · Cited by 139
“In failing hearts, a profibrotic role was attributed for miR-21.(6) Therapeutic”
BackgroundSelf-citationInduced Pluripotent Stem Cells in Cardiovascular Drug Discovery
Mercola, M., Colas, A., & Willems, E. (2013) · Circulation Research · doi:10.1161/circresaha.111.250266 · Cited by 122
Hromadníková, I., Kotlabová, K., Hympanova, L. H., & Krofta, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138383 · Cited by 131
MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling
Wei, J., Feng, L., Zhong, L., Xu, G., & Fan, X. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.03.014 · Cited by 132
“Most importantly, injection of chemically modified antisense oligonucleotides specific for miR-21 (antagomiR-21) into mice subjected to pressure overload of the left ventricle by transverse aortic constriction (TAC) reduces myocardial fibrosis [7].”
BackgroundMicroRNAs: potential mediators and biomarkers of diabetic complications
Kato, M. V., Castro, N., & Natarajan, R. D. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.009 · Cited by 137
“It is worthwhile to determine whether these miRNAs also play a role in diabetic heart disease [112–114].”
Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis
Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., Guttridge, D. C., Sun, H., & Wang, H. (2012) · Molecular Therapy · doi:10.1038/mt.2012.35 · Cited by 122
Dynamically regulated miRNA-mRNA networks revealed by exercise
Tonevitsky, A. G., Maltseva, D. V., Abbasi, A., Samatov, T. R., Sakharov, D. A., Shkurnikov, M. U., Lebedev, A. E., Galatenko, V. V., Grigoriev, A. I., & Northoff, H. (2013) · BMC Physiology · doi:10.1186/1472-6793-13-9 · Cited by 122
“The expression level of hsa-miR-21-5p itself is known to be stress-responsive and play an important role in heart failure [29] and renal ischemia reperfusion injury [30].”
BackgroundWong, L., Wang, J., Liew, O., Richards, A., & Chen, Y.-T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040502 · Cited by 121
“miR-21 targets key molecules in the signaling pathways that govern cardiac fibrosis, hypertrophy and apoptosis [150,153,154].”
BackgroundThe Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis
Ji, X., Wu, B., Fan, J., Han, R., Luo, C., Wang, T., Yang, J., Han, L., Zhu, B., Wei, D., et al. (2015) · Scientific Reports · doi:10.1038/srep14131 · Cited by 130
microRNAs in cardiovascular disease – clinical application
Schulte, C., Karakas, M., & Zeller, T. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0576 · Cited by 133
Roca-Alonso, L., Castellano, L., Mills, A., Dabrowska, A. F., Sikkel, M. B., Pellegrino, L., Jacob, J., Frampton, A. E., Krell, J., Coombes, R. C., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.89 · Cited by 118
Pandey, A. K., Verma, G., Vig, S., Srivastava, S. P., Srivastava, R., & Datta, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.004 · Cited by 132
Carbon nanotube-based label-free electrochemical biosensor for sensitive detection of miRNA-24
Li, F., Peng, J., Wang, J., Tang, H., Tan, L., Xie, Q., & Yao, S. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.10.061 · Cited by 122
“Moreover, recent studies have shown that miRNAs are linked with the onset of cancer and other diseases (Calin et al., 2002; Chan et al., 2005; Huang et al., 2008), which are dependent on the miRNA expression levels (Thum et al., 2008; Xiao and Rajewsky, 2009).”
BackgroundReceptor control in mesenchymal stem cell engineering
Dalby, M. J., García, A. J., & Salmerón‐Sánchez, M. (2018) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.91 · Cited by 128
Shih, Y.-C., Chen, C.-L., Zhang, Y., Mellor, R. L., Kanter, E. M., Fang, Y. H., Wang, H.-C., Hung, C., Nong, J.-Y., Chen, H.-J., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312130 · Cited by 124
MicroRNA Let-7i Negatively Regulates Cardiac Inflammation and Fibrosis
Wang, X., Wang, H., Li, Y., Zhang, C., Zhou, C.-Y., Wang, L., Xia, Y., Du, J., & Li, H. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05548 · Cited by 121
Chen, L.-L., Zhang, Z., Yi, Z.-B., & Li, J.-J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.150 · Cited by 104
“In fact, miRNA knockout mice often do not display a specific phenotype, unless they are challenged with a stimulus causing cellular stress in target organs (Thum et al, 2008).”
BackgroundMicroRNAs in Heart Failure: Is the Picture Becoming Less miRky?
Melman, Y. F., Shah, R. V., & Das, S. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000266 · Cited by 134
Olivieri, F., Spazzafumo, L., Bonafè, M., Recchioni, R., Prattichizzo, F., Marcheselli, F., Micolucci, L., Mensà, E., Giuliani, A., Santini, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6164 · Cited by 117
Non-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease
Kataoka, M., & Wang, D. (2014) · Cells · doi:10.3390/cells3030883 · Cited by 123
“For instance, miR-21 was shown to promote cardiac fibroblast survival and the development of cardiac fibrosis by enhancing ERK-MAP kinase activity through the down-regulation of Sprouty homologue 1, a direct target of miR-21 and an endogenous inhibitor of ERK-MAP kinase [24].”
BackgroundZhang, Y., Wang, J.-H., Zhang, Y.-Y., Wang, Y., Wang, J., Zhao, Y., Jin, X., Xue, G., Li, P.-H., Sun, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23010 · Cited by 117
The Expression Levels of Plasma micoRNAs in Atrial Fibrillation Patients
Liu, Z., Zhou, C., Liu, Y., Wang, S., Ye, P., Miao, X., & Xia, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044906 · Cited by 115
“Other miRNAs such as miRNA-21 [11], miRNA-133 and miRNA-590 [53], may also promote AF by stimulating cardiac fibrosis.”
BackgroundHong, C., Chen, X., Liu, T., Li, J., Yang, H., Chen, J., & Chen, G. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.06.040 · Cited by 118
miRNA-Based Therapeutic Strategies
Ishida, M., & Selaru, F. M. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0004-5 · Cited by 134
Quesne, J. P. C. L., & Caldas, C. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.009 · Cited by 136
miR-27b controls venous specification and tip cell fate
Biyashev, D., Veliceasa, D., Topczewski, J., Topczewska, J. M., Мизгирев, И. В., Vinokour, E. I., Reddi, A. L., Licht, J. D., Revskoy, S., & Volpert, O. V. (2011) · Blood · doi:10.1182/blood-2011-07-370635 · Cited by 120
Self-citation
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.